Royalty Pharma plcRPRXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank63
3Y CAGR-78.4%
5Y CAGR-54.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-78.4%/yr
vs +137.7%/yr prior
5Y CAGR
-54.8%/yr
Recent deceleration
Acceleration
-216.1pp
Decelerating
Percentile
P63
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 0.99% |
| Q3 2025 | -83.19% |
| Q2 2025 | 495.05% |
| Q1 2025 | 10000.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | -99.01% |
| Q3 2023 | 10000.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | -99.01% |
| Q4 2022 | 98.04% |
| Q3 2022 | 4107.92% |
| Q2 2022 | -99.40% |
| Q1 2022 | -3.20% |
| Q4 2021 | 14.72% |
| Q3 2021 | 2798.78% |
| Q2 2021 | 18.21% |
| Q1 2021 | -66.05% |
| Q4 2020 | 52.65% |
| Q3 2020 | -11.77% |
| Q2 2020 | -24.39% |
| Q1 2020 | -51.87% |
| Q4 2019 | -30.14% |
| Q3 2019 | 5.88% |
| Q2 2019 | -6.67% |
| Q1 2019 | 0.00% |